Jefferies Financial Group Inc. Lowers Position in Kenvue Inc. (NYSE:KVUE)

Key Points

• Jefferies Financial Group Inc. has reduced its holdings in Kenvue Inc. by 40.7% during the first quarter, now owning 74,106 shares worth approximately $1.78 million.
• Kenvue is increasing its quarterly dividend to $0.2075 per share, representing a yield of 3.8% and a total annualized dividend of $0.83.
• Kenvue's stock showed resilience with a 0.7% increase, amid fluctuating analyst price targets and a consensus rating of "Hold" based on performance expectations.

Jefferies Financial Group Inc. lessened its holdings in Kenvue Inc. (NYSE:KVUE - Free Report) by 40.7% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 74,106 shares of the company's stock after selling 50,894 shares during the quarter. Jefferies Financial Group Inc.'s holdings in Kenvue were worth $1,777,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently bought and sold shares of KVUE. Pittenger & Anderson Inc. bought a new position in Kenvue in the 1st quarter valued at $30,000. TruNorth Capital Management LLC bought a new position in Kenvue in the 1st quarter valued at $36,000. Bank Julius Baer & Co. Ltd Zurich grew its stake in Kenvue by 120.6% in the 1st quarter. Bank Julius Baer & Co. Ltd Zurich now owns 1,699 shares of the company's stock valued at $41,000 after purchasing an additional 929 shares during the period. Clarity Asset Management Inc. bought a new position in Kenvue in the 4th quarter valued at $45,000. Finally, Continuum Advisory LLC grew its stake in Kenvue by 2,071.1% in the 1st quarter. Continuum Advisory LLC now owns 1,954 shares of the company's stock valued at $47,000 after purchasing an additional 1,864 shares during the period. Institutional investors own 97.64% of the company's stock.

Kenvue Stock Up 0.7%

KVUE stock opened at $21.60 on Monday. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.60 and a current ratio of 0.86. The company has a market capitalization of $41.44 billion, a price-to-earnings ratio of 39.27, a PEG ratio of 3.62 and a beta of 0.83. Kenvue Inc. has a fifty-two week low of $18.10 and a fifty-two week high of $25.17. The stock has a fifty day moving average of $21.82 and a 200-day moving average of $22.40.

Kenvue (NYSE:KVUE - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported $0.24 EPS for the quarter, topping the consensus estimate of $0.23 by $0.01. Kenvue had a return on equity of 20.87% and a net margin of 6.90%. The business had revenue of $3.74 billion during the quarter, compared to the consensus estimate of $3.69 billion. During the same quarter last year, the company earned $0.28 EPS. The firm's revenue was down 3.9% compared to the same quarter last year. As a group, equities research analysts predict that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, August 27th. Shareholders of record on Wednesday, August 13th will be paid a $0.2075 dividend. The ex-dividend date is Wednesday, August 13th. This represents a $0.83 annualized dividend and a yield of 3.8%. This is an increase from Kenvue's previous quarterly dividend of $0.21. Kenvue's dividend payout ratio is 149.09%.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on KVUE. Redburn Atlantic began coverage on Kenvue in a research note on Thursday, April 10th. They issued a "neutral" rating and a $23.50 price objective for the company. Bank of America reduced their price objective on Kenvue from $27.00 to $25.00 and set a "buy" rating for the company in a research note on Tuesday, July 15th. JPMorgan Chase & Co. reduced their price objective on Kenvue from $27.00 to $26.00 and set an "overweight" rating for the company in a research note on Friday, July 25th. Barclays reduced their price objective on Kenvue from $23.00 to $22.00 and set an "equal weight" rating for the company in a research note on Tuesday, July 15th. Finally, Citigroup cut their price target on Kenvue from $24.50 to $22.00 and set a "neutral" rating for the company in a research note on Tuesday, July 15th. Seven investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Hold" and an average target price of $24.79.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.

Want to see what other hedge funds are holding KVUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kenvue Inc. (NYSE:KVUE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.